MawiDna
Mawi - Biosampling Reinvented
  • OUR PRODUCTS
  • ABOUT US
    • Careers
    • Our Team
    • Our Technology
    • Worldwide Contacts
  • LEARN
    • Articles & Applications
    • DNA/RNA Extraction methods
    • Blog
    • FAQ
  • CONTACT
Request sample kit arrow

News

  • Active Partnerships
  • Press
  • Blog
    • About Mawi DNA Technolgies
    • Announcements
    • Articles & Cohort Studies
    • Biosampling Technology
    • Events
    • Hematology
    • In The Press
    • iSWAB Insights
    • News
    • Uncategorized
  • Blog
  • Articles & Cohort Studies

De Novo SIX1 Variant and Nonsyndromic Cochleovestibular Nerve Abnormality

Oct 14, 2019

De Novo SIX1 Variant and Nonsyndromic Cochleovestibular Nerve Abnormality

Abstract

Background: Childhood hearing impairment affects language and cognitive development. Profound congenital sensorineural hearing impairment can be due to an abnormal cochleovestibular nerve (CVN) and cochleovestibular malformations, however, the etiology of these conditions remains unclear.

Methods: We used a trio‐based exome sequencing approach to unravel the underlying molecular etiology of a child with a rare nonsyndromic CVN abnormality and cochlear hypoplasia. Clinical and imaging data were also reviewed.

Results: We identified a de novo missense variant [p(Asn174Tyr)] in the DNAbinding Homeodomain of SIX1, a gene which previously has been associated with autosomal dominant hearing loss (ADHL) and branchio‐oto‐renal or Branchio‐otic syndrome, a condition not seen in this patient.

Conclusions: SIX1 has an important function in otic vesicle patterning during embryogenesis, and mice show several abnormalities to their inner ear including loss of inner ear innervation. Previous reports on patients with SIX1 variants lack imaging data and nonsyndromic AD cases were reported to have no inner ear malformations. In conclusion, we show that a de novo variant in SIX1 in a patient with sensorineural hearing loss leads to cochleovestibular malformations and abnormalities of the CVN, without any other abnormalities. Without proper interventions, severe to profound hearing loss is devastating to both education and social integration. Choosing the correct intervention can be challenging and a molecular diagnosis may adjust intervention and improve outcomes, especially for rare cases.

For more information, see the full paper here

Related news

Mar 13, 2025

A Journey of Innovation and Vision – The Mawi Story…...

Mawi was founded with one major goal: to simplify sample collection, transportation, and storage while making the process as painless as possible, especially for babies and the elderly. The collected ...

READ MORE
Oct 13, 2024

Mawi DNA Technologies Partners with GenoBank.io To Tokenize Our Groundbreaking…...

October 14, 2024 – We are thrilled to announce that Mawi DNA Technologies has officially partnered with READ MORE

Oct 09, 2024

Mawi DNA Partners with Tempus AI and Tally Health™ to…...

October 7, 2024 – Customers frequently ask what swabs are compatible with our iSWAB® non-invasive sample collection technology. Although most swab types can be used with our system, incl...

READ MORE

Join our mailing list for updates and news about mawi

      • Our Products
      • FAQ
      • About Us
      • Contact
      • Resources
      • Blog
      • Sitemap

    Mawi DNA Technologies LLC

    1252 Quarry Lane Suite A,
    Pleasanton, CA | 94566

    Telephone: 510-256-5186

    Toll-Free: 855-DNA-SWAB

    LinkedinLinkedin TwitterTwitter YoutubeYoutube

    Copyright © 2024 Mawi DNA Technologies LLC.

    mawi-hemasure-sample mawi-hemasure-sample-new

    Download our free documents